Valrubicin in refractory non-muscle invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 15, Issue 12, 2015, Pages 1379-1387

  Sharma, Pranav ^a   Zargar Shoshtari, Kamran ^a   Sexton, Wade J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BCG refractory; clinical trials; intravesical agents; non muscle invasive bladder cancer; valrubicin

Indexed keywords

DOCETAXEL; GEMCITABINE; MITOMYCIN; VALRUBICIN; ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CYSTOSCOPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE UTILIZATION; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MORBIDITY; MORTALITY; NEUTROPENIA; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEIC ACID METABOLISM; PANCYTOPENIA; REFRACTORY NON MUSCLE INVASIVE BLADDER CANCER; SURVIVAL RATE; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84949320252     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1115350     Document Type: Article

References (50)

1. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56: 185-229.
2. Blum RH, Garnick MB, Israel M, et al. Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res. 1981; 76: 7.
3. Onrust SV, Lamb HM. Valrubicin. Drugs & Aging. 1999; 15: 69-75.
4. Shen Z, Shen T, Wientjes MG, et al. Intravesical treatments of bladder cancer: review. Pharm Res. 2008; 25: 1500.
5. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011; 186: 2158-2167.
6. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178: 2314.
7. Montie JE, Abrahams NA, Bahnson RR, et al. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006; 4: 984.
8. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003; 169: 90.
9. Pansadoro V, Emiliozzi P, De Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology. 2002; 59: 227.
10. Bostrom PJ, Kossi J, Laato M, et al. Risk factors for mortality and morbidity related to radical cystectomy. BJU Int. 2009; 103: 191.
11. Liberman D, Lughezzani G, Sun M, et al. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011; 77: 660.
12. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007; 109: 1756-1762.
13. Jarow JP, Lerner SP, Kluetz PG, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014; 83: 262-265.
14. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997; 49: 471-475.
15. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000; 163: 761-767.
16. Newling DW, Hetherington J, Sundaram SK, et al. The use of valrubicin for the chemoresection of superficial bladder cancer-a marker lesion study. Eur Urol. 2001; 39: 643-647.
17. Ignatoff JM, Chen YH, Greenberg RE, et al. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009; 27: 496-501.
18. Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol. 2013; 31: 1635-1642.
19. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000; 56: 232-235.
20. Agents Pending FDA Approval, Filed by Manufacturer. Current FDA-related drug information. Hosp Pharm. 2010; 44: 700.
21. Steinberg GD, Smith ND, Ryder K, et al. Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. Postgrad Med. 2011; 123: 28-34.
22. Cookson MS, Chang SS, Lihou C, et al. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014; 6: 181-191.
23. Ahn JJ, Ghandour RA, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory nonmuscle invasive bladder cancer. Curr Opin Urol. 2014; 24: 540-545.
24. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology. 1997; 49: 687-691.
25. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001; 40: 144.
26. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006; 24: 2729-2734.
27. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. J Urol. 2013; 190: 1200-1204.
28. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006; 24: 3075-3080.
29. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010; 75: 134-137.
30. Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009; 27: 331-335.
31. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol. 2013; 189: 834-839.
32. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003; 170: 777-782.
33. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011; 12: 871.
34. Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology. 1998; 51: 506-509.
35. Gingrich JR. Bladder cancer: chemohyperthermia for bladder cancer-clinically effective Nat Rev Urol. 2011; 8: 414-416.
36. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81-93.
37. Arends TJ, Van Der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014; 192: 708-713.
38. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009; 182: 1313.
39. Lee JY, Diaz RR, Cho KS, et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy. J Urol. 2013; 190: 1192-1199.
40. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64: 639-653.
41. Kamat AM, Witjes JA, Brausi M, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014; 192: 305-315.
42. Nielsen ME, Smith AB, Pruthi RS, et al. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int. 2012; 110: 967-972.
43. Marchetti A, Wang L, Magar R, et al. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther. 2000; 22: 422-438.
44. Cutress ML, Stewart GD, Zakikhani P, et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012; 110: 614-628.
45. Argyropoulos AN, Tolley DA. Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approaches. BJU Int. 2007; 99: 982-987.
46. Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer. 2003; 98: 55-60.
47. Audenet F, Traxer O, Bensalah K, et al. Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes. World J Urol. 2013; 31: 45-52.
48. Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit Eur Urol. 2011; 60: 955-960.
49. Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy Urology. 2009; 73: 27-31.
50. Margulis V, Youssef RF, Karakiewicz PI, et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol. 2010; 184: 453-458.